Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Yuxuan Che, Ruolan Zeng, Dabei Tang, Ou Bai, Youchao Jia, Yuhuan Gao, Xiaojing Yan, Xiaolei Ding, Xiuli Sun, Xiaobo Wang, Bing Xu, Hui-Han Wang, Dongxia Qu, Liye Xu, Na Li, Qingyuan Zhang, Hui Zhou, Xiuhua Sun

Blood (2025) 146 (Supplement 1): 7142.

https://doi.org/10.1182/blood-2025-7142

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Untargeted metabolomics and machine learning reveal novel non-invasive biomarker panels for diagnosis and risk stratification in extranodal NK/T-cell lymphoma

Yajun Li, Kailin Chen, Hui Zhou

Blood (2025) 146 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2025-7082

Published: 2025

Journal Articles

The research on the immune microenvironment of patients with relapse or refractory diffuse large b faced drug resistance to CD20/CD3 bispecific antibodies

Shujuan Wen, Shan Li, Yiwei Zhou, Mei Wu, Yong Sun, Lin Zhu, Xin Hu, Li Guo, Hui Zhou

Blood (2025) 146 (Supplement 1): 7073.

https://doi.org/10.1182/blood-2025-7073

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

Blood (2025) 146 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2025-1843

Published: 2025

Journal Articles

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Hang Yang, Peng SUN, Panpan LIU, Yu Wang, Hui Zhou, Ying Lu, Lu Zhang, Keshu Zhou, Zhiming Li

Blood (2025) 146 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2025-1922

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Blood (2025) 146 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2025-7229

Published: 2025

Journal Articles

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Yan Gao, Li-Qin Ping, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2025-5375

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Jing Li, Zhenyu Li, Chunrui Li, Pengcheng He, Jun Luo, Rong Fu, Liye Zhong, Hang Quach, Jay Hocking, Peter Presgrave, Xiaoyi Tang, Wen Zhang, Jinchao Gao, Luyin Ding, Peiqi Li, Hui Zhou, Peng Liu

Blood (2025) 146 (Supplement 1): 702.

https://doi.org/10.1182/blood-2025-702

Published: 2025

Journal Articles

Prophylaxis with thiotepa and high-dose methotrexate showed lower central nervous system relapse rate in high-risk diffuse large B-cell lymphoma

Ruolan Zeng, Zhou Ouyang, Yinhua Liu, Xiaoyan Chen, Qianyin Ouyang, Yin Wu, Ling Xiao, Hui Zhou

Blood (2025) 146 (Supplement 1): 3695.

https://doi.org/10.1182/blood-2025-3695

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Blood (2025) 146 (Supplement 1): 776.

https://doi.org/10.1182/blood-2025-776

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Li Wang, Guo Zhang, Hui Zhou, Ting Niu

Blood (2024) 144 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2024-207718

Published: 2024

Journal Articles

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Chen Xia, Yajun Li, Zhongyi Sun, Lijun Huang, Ruolan Zeng, Yizi He, Caiqin Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2024-200882

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Untargeted metabolomics and machine learning reveal novel non-invasive biomarker panels for diagnosis and risk stratification in extranodal NK/T-cell lymphoma

The research on the immune microenvironment of patients with relapse or refractory diffuse large b faced drug resistance to CD20/CD3 bispecific antibodies

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Prophylaxis with thiotepa and high-dose methotrexate showed lower central nervous system relapse rate in high-risk diffuse large B-cell lymphoma

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only